Semaglutide, tirzepatide and retatrutide: a wholesale supply guide for pharmacies and telehealth

This is a supply guide, not a clinical one. The prescriber decides what to prescribe; the pharmacy decides what it can lawfully compound. What follows is what buyers ask us about sourcing these three compounds.

Semaglutide

The highest-volume compound in the category and the one with the longest history of pharmacy compounding. Available as bulk API and as pre-weighed lyophilized vials from 5 mg to 30 mg. Paired B12 kits are common for pharmacies compounding combination vials. Demand is steady, so allocated monthly inventory is straightforward to arrange.

Tirzepatide

A dual GIP/GLP-1 receptor agonist with higher per-patient milligram requirements than semaglutide, so vial sizes run larger (10 mg to 60 mg) and monthly volumes climb faster than patient counts suggest. Budget API by total milligrams per month, not by patient.

Retatrutide

A triple agonist still in clinical development. It is supplied as a research-use material, and pharmacies should confirm bulk-substance eligibility and the current regulatory status in their state before considering it for compounding. Supply is tighter and lead times longer than the other two.

Documentation for all three

Lot-specific CoA with HPLC purity, LC-MS identity and net peptide content is the minimum. Because these compounds attract regulatory attention, pedigree documentation and a supplier qualification packet matter more here than on any other SKU.

Regulatory status changes

Compounding eligibility for GLP-1 compounds has shifted repeatedly as shortage designations change. Your supplier should tell you when status changes and should never claim a product is "approved for compounding." Keep counsel involved.

Verified accounts see current sizes, MOQs and lead times for all three in the catalog.